SML3129

NIK SMI1

≥95% (HPLC)

• Synonym(e): (R)-6-(3-((3-Hydroxy-1-methyl-2-oxopyrrolidin-3-yl)-ethynyl)phenyl)-4-methoxypicolinamide, 6-[3-[2-[(3R)-3-Hydroxy-1-methyl-2-oxo-3-pyrrolidinyl]ethynyl]phenyl]-4-methoxy-2-pyridinecarboxamide, NIK small molecule inhibitor 1, NIK-SMI1
• Empirische Formel (Hill-System): C₂₀H₁₉N₃O₄
• CAS-Nummer: 1660114-31-7
• Molekulargewicht: 365.38
• MDL-Nummer: MFCD31715434
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥95% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 2 mg/mL, clear
• Lagertemp.: 2-8°C
• SMILES String: NC(C1=NC(C2=CC(C#C[C@]3(C(N(CC3)C)=O)O)=CC=C2)=CC(OC)=C1)=O
• InChI: 1S/C20H19N3O4/c1-23-9-8-20(26,19(23)25)7-6-13-4-3-5-14(10-13)16-11-15(27-2)12-17(22-16)18(21)24/h3-5,10-12,26H,8-9H2,1-2H3,(H2,21,24)/t20-/m0/s1
• InChIKey: LQSHXYHWYGKAMX-FQEVSTJZSA-N

Beschreibung

Biochem./physiol. Wirkung

NIK SMI1 is an orally active, ATP site-targeting, potent and selective NF-κB-inducing kinase inhibitor (h/m NIK IC50 = 230/395 pM; hKHS1/hPKD1/hLRRK2 = 49.6/75.2/247.8 nM) that selectively disrupts noncanonical NF-κB signaling (anti-LTβR-induced p52 nuclear translocation IC50 = 70 nM; TNFα-induced p65 RelA nuclear translocation IC50 >2 μM). SMI1 inhibits BAFF receptor- and CD40-mediated singling in cultures (human and murine B-cells) and shows in vivo efficacy in the NZB/W F1 murine experimental lupus model (6-400 mg/kg/day, b.i.d. p.o.).

Orally active NF-κB-inducing kinase (NIK) inhibitor that selectively disrupts noncanonical NF-κB activation with in vivo efficacy in murine experimental lupus model.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable